ASH News Daily 2016 - Issue 2 - A-24


ASH News Daily

Page A-24

Sunday, December 4, 2016

®

Myeloma
«« From Page A-8

the biological insights of myeloma
were presented by Drs. Erming Tian
and Paola Neri yesterday. Dr. Tian
(abstract #115) discussed research
on MYC abnormalities. These occur by a variety of mechanisms, but
translocations of MYC were unique
in newly diagnosed myeloma compared with MGUS and smoldering
myeloma. It will be interesting to
see whether these findings can tie
into research being done with BET
bromodomain inhibitors, such as
that being presented Monday by Dr.
Geoffrey Matthews (abstract #1062)
on the biology of c-MYC related to
this compound, and this morning by
Dr. Carlos Fernandez de Larrea (abstract #308) on which BET bromodomain blockade enhances Ikaros
inhibition by lenalidomide. Speaking of Ikaros, yesterday Dr. Neri
(abstract #120) clinically correlated
that splicing of cereblon exon 10 can
impair the cytotoxicity of lenalidomide. IMiDs depend on cereblon,
a protein component of the ubiquitin proteasome pathway triggering
proteasomal degredation of IKZF1
(Ikaros) and IKZF3 (Aiolos). Using
samples from her institution and

validating the findings with samples
from the CoMMpass trial, she demonstrated that survival was inferior
in subjects with high levels of spliced
cereblon treated with IMiDs. Per Dr.
Neri, "Our work on the mechanism
of IMiD resistance can be potentially
used as a biomarker to predict sensitivity or resistance to IMiD therapy."
It is encouraging to learn of a clinically relevant biomarker for therapeutic selection in myeloma, which
is desperately deficient.
Minimal residual disease (MRD)
continues to be a hot topic for myeloma. One presentation of particular interest was by Dr. Herve
Avet-Loiseau (abstract #246) who
evaluated MRD by ClonoSEQ in
subjects enrolled in the daratumumab combination trials CASTOR and POLLUX (updates on
these trials will be presented Monday by Dr. Maria-Victoria Mateos
in abstract #1150 and by Dr. Saad
Usmani in abstract #1151). The addition of daratumumab resulted in
remarkably higher MRD-negative
status with resultant improvement
in progression-free survival. Incidentally, Dr. Usmani will also be
presenting research on the feasibility of subcutaneous administration
of daratumumab on Monday (ab-

American Society of Hematology
Self-Assessment Program
(ASH -SAP)
CONFERENCE
®

®

SPECIAL

NEW! SIXTH EDITION

10%
OFF

The Premier Self-Assessment
Program for Hematologists
The Sixth edition of ASH-SAP covers the full
spectrum of adult & pediatric hematology including
benign and malignant disorders.

23
285
6

Pertinent chapters-7 with multimedia
featuring 3D animation & audio
New questions with multiple choice answers
Tests-earn up to 70 CME/MOC credits

stract #1149).
Other must-see upcoming presentations include Dr. Christoph
Driessen's research (abstract #487)
on the combination of HIV protease inhibitor nelfinavir, bortezomib,
and dexamethasone. PI resistance
can be driven by downregulation of
unfolded protein response (UPR).
Nelfinavir triggers activation of
UPR, and thus serves as a basis to
overcome PI resistance. Two exciting presentations on the BCL-2 inhibitor venetoclax will be presented.
Dr. Shaji Kumar (abstract #488) will
present phase I monotherapy results with venetoclax. In this study,
the majority of responses occur in
patients with t(11;14). This indi-

cates a favorable BCL-2 expression
profile. The second presentation, by
Dr. Philippe Moreau (abstract #975),
will report findings from combination venetoclax, bortezomib, and
dexamethasone. It will be important to learn of any differences in
outcomes for subjects with t(11;14).
B-cell maturation antigen (BCMA)
is another critical therapeutic target.
On Monday, Dr. Adam Cohen (abstract #1148) will present results of
a study on GSK 2857915, a humanized IgG1 anti-BCMA antibody conjugated to microtubule disrupting
agent monomethyl auristatin-F.

Pregnancy

ment possibilities for women with
HELLP. Quantifying the absolute
risk of venous thromboembolism
in pregnant patients with essential
thrombocythemia (abstract #595,
Sunday poster session) and characterizing the clinical course of aplastic anemia in pregnancy (abstract
#3909, Monday poster session) will
also be presented.
Last but not least, the education
session titled "Disorders of Hemostasis and Thrombosis in Women's
Health," taking place today at 7:30
a.m. (Room 29, San Diego Convention Center), will feature presentations from Drs. Terry Gernsheimer
and Mary Cushman on the diagnosis and management of inherited
and acquired bleeding disorders,
venous thromboembolism, and
stroke in pregnancy.

«« From Page A-23

E. van Mens presented data on
the critical role of protein C activation by thrombomodulin to prevent
pregnancy loss. In a mouse model,
the embryonic deaths caused by
thrombomodulin (Thbd) deficiency
were prevented by combining Thbd-null mice with genetic supplementation of activated protein C.
Preservation of Thbd function in
the placenta also prevented intrauterine lethality. In another Saturday oral session, Dr. Yoko Yoshida
reported on a major reduction of
free ADAMTS13 antigen detected
by isoelectric focusing gel analysis
in women with HELLP (hemolysis,
elevated liver enzymes, and low
platelets) syndrome when compared to women without HELLP,
opening the door to further research into the diagnostic and treat-

#ASH16
@LLSusa

Dr Carl June: Emily Whitehead first pediatric patient
treated with CAR-T four years
cancer free #ASH16 #immunotherapy

@drrdean
SPECIAL CONFERENCE PRICES
Premier + CME/MOC

10% Off

Print and online Textbook, print Q & A Book, and online CME/MOC exam

Member - Active and International

$490

$441

Member - U.S. & International Associate

$360

$324

Member - Graduate/Medical Student/Resident

$250

$225

Non-member

$630

$567

Digital + CME/MOC

10% Off

Online textbook and CME/MOC exam

Member - Active and International

$380

$342

Member - U.S. & International Associate

$250

$225

Member - Graduate/Medical Student/Resident

$150

$135

Non-member

$520

$468

hematology.org/BuyASHSAP6

Three time zones from home,
Late to bed, early to rise
-- Coffee, you're the best.
#ASH16 #ASHaiku

Dr. Cornell has no relevant conflicts
of interest.

Dr. Skeith has no relevant conflicts
of interest.

@wingchi_leung

Seven thirty dash For newest
haem stash in ASH Awesome
research
flash
#ASHaiku
#ASH16

@crowthrm

Dr Hardeep Singh presenting
@ #ASH16 Special Symposium on Quality. Great talk
on trials and tribulations of
EMRs/HIT @ASH_hematology

@christinemphmd

Stellar, inspirational presentation by Dr. Middledorp: It's
all or nothing. Investigate,
Collaborate! Follow your
heart !#ASH16 #ASHTrainee

Sunday Schedule Changes
Speaker Change:
For the Education Program session titled "Treatment of Congenital
Bleeding Disorders," taking place today at 7:30 a.m., speaker Dr. Flora
Peyvandi Ribic is unable to attend and has arranged for Dr. Amy Shapiro to give the talks in her stead.



Table of Contents for the Digital Edition of ASH News Daily 2016 - Issue 2

ASH News Daily 2016 - Issue 2 - A-1
ASH News Daily 2016 - Issue 2 - A-2
ASH News Daily 2016 - Issue 2 - A-3
ASH News Daily 2016 - Issue 2 - A-4
ASH News Daily 2016 - Issue 2 - A-5
ASH News Daily 2016 - Issue 2 - A-6
ASH News Daily 2016 - Issue 2 - A-7
ASH News Daily 2016 - Issue 2 - A-8
ASH News Daily 2016 - Issue 2 - A-9
ASH News Daily 2016 - Issue 2 - A-10
ASH News Daily 2016 - Issue 2 - A-11
ASH News Daily 2016 - Issue 2 - A-12
ASH News Daily 2016 - Issue 2 - A-13
ASH News Daily 2016 - Issue 2 - A-14
ASH News Daily 2016 - Issue 2 - A-15
ASH News Daily 2016 - Issue 2 - A-16
ASH News Daily 2016 - Issue 2 - A-17
ASH News Daily 2016 - Issue 2 - A-18
ASH News Daily 2016 - Issue 2 - A-19
ASH News Daily 2016 - Issue 2 - A-20
ASH News Daily 2016 - Issue 2 - A-21
ASH News Daily 2016 - Issue 2 - A-22
ASH News Daily 2016 - Issue 2 - A-23
ASH News Daily 2016 - Issue 2 - A-24
ASH News Daily 2016 - Issue 2 - A-25
ASH News Daily 2016 - Issue 2 - A-26
ASH News Daily 2016 - Issue 2 - B-1
ASH News Daily 2016 - Issue 2 - B-2
ASH News Daily 2016 - Issue 2 - B-3
ASH News Daily 2016 - Issue 2 - B-4
ASH News Daily 2016 - Issue 2 - B-5
ASH News Daily 2016 - Issue 2 - B-6
ASH News Daily 2016 - Issue 2 - B-7
ASH News Daily 2016 - Issue 2 - B-8
ASH News Daily 2016 - Issue 2 - B-9
ASH News Daily 2016 - Issue 2 - B-10
ASH News Daily 2016 - Issue 2 - B-11
ASH News Daily 2016 - Issue 2 - B-12
ASH News Daily 2016 - Issue 2 - B-13
ASH News Daily 2016 - Issue 2 - B-14
ASH News Daily 2016 - Issue 2 - B-15
ASH News Daily 2016 - Issue 2 - B-16
ASH News Daily 2016 - Issue 2 - B-17
ASH News Daily 2016 - Issue 2 - B-18
ASH News Daily 2016 - Issue 2 - B-19
ASH News Daily 2016 - Issue 2 - B-20
ASH News Daily 2016 - Issue 2 - B-21
ASH News Daily 2016 - Issue 2 - B-22
ASH News Daily 2016 - Issue 2 - B-23
ASH News Daily 2016 - Issue 2 - B-24
ASH News Daily 2016 - Issue 2 - B-25
ASH News Daily 2016 - Issue 2 - B-26
ASH News Daily 2016 - Issue 2 - B-27
ASH News Daily 2016 - Issue 2 - B-28
ASH News Daily 2016 - Issue 2 - B-29
ASH News Daily 2016 - Issue 2 - B-30
ASH News Daily 2016 - Issue 2 - B-31
ASH News Daily 2016 - Issue 2 - B-32
ASH News Daily 2016 - Issue 2 - B-33
ASH News Daily 2016 - Issue 2 - B-34
ASH News Daily 2016 - Issue 2 - B-35
ASH News Daily 2016 - Issue 2 - B-36
ASH News Daily 2016 - Issue 2 - B-37
ASH News Daily 2016 - Issue 2 - B-38
ASH News Daily 2016 - Issue 2 - B-39
ASH News Daily 2016 - Issue 2 - B-40
ASH News Daily 2016 - Issue 2 - B-41
ASH News Daily 2016 - Issue 2 - B-42
ASH News Daily 2016 - Issue 2 - B-43
ASH News Daily 2016 - Issue 2 - B-44
ASH News Daily 2016 - Issue 2 - B-45
ASH News Daily 2016 - Issue 2 - B-46
ASH News Daily 2016 - Issue 2 - B-47
ASH News Daily 2016 - Issue 2 - B-48
ASH News Daily 2016 - Issue 2 - C-1
ASH News Daily 2016 - Issue 2 - C-2
ASH News Daily 2016 - Issue 2 - C-3
ASH News Daily 2016 - Issue 2 - C-4
ASH News Daily 2016 - Issue 2 - C-5
ASH News Daily 2016 - Issue 2 - C-6
ASH News Daily 2016 - Issue 2 - C-7
ASH News Daily 2016 - Issue 2 - C-8
ASH News Daily 2016 - Issue 2 - C-9
ASH News Daily 2016 - Issue 2 - C-10
ASH News Daily 2016 - Issue 2 - C-11
ASH News Daily 2016 - Issue 2 - C-12
ASH News Daily 2016 - Issue 2 - C-13
ASH News Daily 2016 - Issue 2 - C-14
ASH News Daily 2016 - Issue 2 - C-15
ASH News Daily 2016 - Issue 2 - C-16
ASH News Daily 2016 - Issue 2 - C-17
ASH News Daily 2016 - Issue 2 - C-18
ASH News Daily 2016 - Issue 2 - C-19
ASH News Daily 2016 - Issue 2 - C-20
ASH News Daily 2016 - Issue 2 - C-21
ASH News Daily 2016 - Issue 2 - C-22
ASH News Daily 2016 - Issue 2 - C-23
ASH News Daily 2016 - Issue 2 - C-24
ASH News Daily 2016 - Issue 2 - C-25
ASH News Daily 2016 - Issue 2 - C-26
https://www.nxtbookmedia.com